CHELSEA VILICICH: Open Payments
NPI 1003408113 · NEWPORT BEACH, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,351 in 142 payments from 19 companies in 2025. Trend: 2023 $3,637 · 2024 $3,421 · 2025 $3,351
Food & beverage: $3,351
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 19 | $561 |
| Vanda Pharmaceuticals Inc. | 16 | $521 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 22 | $479 |
| Otsuka America Pharmaceutical, Inc. | 13 | $330 |
| Janssen Pharmaceuticals, Inc | 6 | $178 |
| Bausch Health US, LLC | 8 | $161 |
| Axsome Therapeutics, Inc. | 7 | $158 |
| Alkermes, Inc. | 11 | $147 |
| Lundbeck LLC | 7 | $143 |
| E.R. Squibb & Sons, L.L.C. | 4 | $120 |
Products named: INGREZZA, CAPLYTA, HETLIOZ, ABILIFY ASIMTUFII, REXULTI, SPRAVATO, APLENZIN, Auvelity.
Industry payments across CA — which companies pay providers there.
